{
    "clinical_study": {
        "@rank": "42028", 
        "acronym": "RASET", 
        "arm_group": [
            {
                "arm_group_label": "Rivaroxaban", 
                "arm_group_type": "Experimental", 
                "description": "Rivaroxaban 10mg tablet daily for 45 days"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet daily for 45 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre\n      trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg\n      Superficial Vein Thrombosis (>  or = 5cm) that otherwise would not initially be treated with\n      anticoagulant therapy."
        }, 
        "brief_title": "Rivaroxaban Anticoagulation for Superficial Vein Thrombosis", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Symptomatic Superficial Vein Thrombosis", 
        "condition_browse": {
            "mesh_term": [
                "Thrombosis", 
                "Venous Thrombosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with symptomatic superficial leg thrombosis will be randomized into two arms, a)\n      rivaroxaban 10mg 1 tablet daily for 45 days or b) placebo to determine if rivaroxaban (10 mg\n      once daily) is an effective and safe treatment for superficial vein thrombosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -  Symptomatic Superficial Vein Thrombosis of the leg of \u22655 cm length (diagnosed\n        clinically or with ultrasound)\n\n        Exclusion Criteria:\n\n          -  Age  <18 years\n\n          -  Symptoms >21 days\n\n          -  Receiving an anticoagulant for another indication (example: atrial fibrillation) when\n             Superficial Vein Thrombosis started.\n\n          -  Superficial Vein Thrombosis already treated with >1 dose of anticoagulant (example.\n             fondaparinux or Low Molecular Weight Heparin).\n\n          -  Planned treatment of Superficial Vein Thrombosis with a course of anticoagulant\n             therapy.\n\n          -  Another indication for anticoagulant therapy (example. Deep Vein Thrombosis,\n             Pulmonary Embolism, atrial fibrillation).\n\n          -  Judged to require immediate ligation of the saphenofemoral junction or stripping of\n             thrombosed varicose veins.\n\n          -  proximal Deep Vein Thrombosis or Pulmonary Embolism within the past 5 years.\n\n          -  Superficial Vein Thrombosis associated with sclerotherapy or an intravenous canula.\n\n          -  A high risk of bleeding as evidenced by any of the following:\n\n               1. Active bleeding\n\n               2. Bleeding within the past 30 days due to a cause that has not fully resolved.\n\n               3. Known or expected thrombocytopenia with a platelet count of less than 80,000 x\n                  10 9/L.\n\n               4. History of ever having had spontaneous intracranial bleeding, or any\n                  intracranial bleeding within the past 3 months.\n\n               5. Receiving dual antiplatelet therapy (example. aspirin and clopidogrel).\n\n          -  Elevated creatinine level is suspected and creatinine clearance has not been\n             estimated, OR creatinine clearance (Cockcroft-Gault equation) of less than 30 ml/min.\n\n          -  Clinically relevant hepatic disease (including Child-Pugh B and C) is known or\n             suspected (example., associated with: International Normalized Ratio >1.7; total\n             bilirubin >2 upper limit of normal; or Alanine aminotransferase (ALT) or Aspartate\n             aminotransferase (AST)  >3 times upper limit of normal).\n\n          -  Ongoing requirement for systemic treatment with azole-antimycotics (except\n             fluconazole),  Human Immunodeficiency Virus (HIV) -protease inhibitors, or strong\n             Cytochrome P450 3A4 (CYP3A4) inducers due to the potential interaction with\n             rivaroxaban.\n\n          -  Pregnant or lactating women, or at risk of becoming pregnant.\n\n          -  Life expectancy less than 90 days\n\n          -  Patient is unwilling or unable to comply with the protocol (example. unable to attend\n             follow-up visits because of geographic inaccessibility).\n\n          -  Participating in a competing clinical investigation and receiving any other\n             investigational agent(s)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02123524", 
            "org_study_id": "OCOG-2013-RASET"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rivaroxaban", 
                "intervention_name": "Rivaroxaban", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Superficial Vein Thrombosis", 
        "lastchanged_date": "April 28, 2014", 
        "link": {
            "url": "http://www.ocog.ca"
        }, 
        "location": {
            "contact": {
                "email": "stevensp@mcmaster.ca", 
                "last_name": "Pamela Stevens, RN", 
                "phone": "905-521-2100", 
                "phone_ext": "43784"
            }, 
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8V1C3"
                }, 
                "name": "Juravinski Hospital"
            }, 
            "investigator": {
                "last_name": "Clive Kearon, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis", 
        "overall_contact": {
            "email": "ruddl@mcmaster.ca", 
            "last_name": "Lisa N Rudd-Scott, RN BScN MN", 
            "phone": "905-527-2299", 
            "phone_ext": "43793"
        }, 
        "overall_contact_backup": {
            "email": "spadafl@mcmaster.ca", 
            "last_name": "Luciana Spadafora", 
            "phone": "905-527-2299", 
            "phone_ext": "42655"
        }, 
        "overall_official": {
            "affiliation": "McMaster University/ Hamilton Health Sciences, Juravinski Hospital", 
            "last_name": "Clive Kearon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "Canada: Ethics Review Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\"Treatment failure\" at 90 days (composite of: treated with non-study anticoagulant therapy; proximal Deep Vein Thrombosis or Pulmonary Embolism; surgery for Superficial Vein Thrombosis).", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "90 days"
            }, 
            {
                "description": "Major bleeding within 90 days.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "90 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02123524"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The patient will self assess any change in leg pain using a Likert Scale.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Baseline,Day 7, Day 45 and Day 90"
            }, 
            {
                "description": "Patients will rate any change in venous disease-specific quality of life (QOL) (VEINES-QOL and VEINES-Symptoms) and general health-related QOL (SF-36v2) at 45 days", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 45"
            }, 
            {
                "description": "Any use of oral analgesics and oral/topical anti-inflammatory agents.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "Baseline, day 7, day 45 and day 90"
            }, 
            {
                "description": "Death", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "90 days"
            }, 
            {
                "description": "major and minor bleeding", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "45 days"
            }
        ], 
        "source": "McMaster University", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "McMaster University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}